A Study To Examine The Safety, Tolerability And Pharmacokinetics Of PF-02545920 In Psychiatrically Stable Subjects With Schizophrenia
| Status: | Completed |
|---|---|
| Conditions: | Schizophrenia |
| Therapuetic Areas: | Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | 18 - 55 |
| Updated: | 8/22/2018 |
| Start Date: | March 6, 2013 |
| End Date: | October 17, 2013 |
A Randomized, Double-blind, Placebo Controlled, Sponsor Open, Phase 1b Study To Examine The Adjunctive Safety, Tolerability And Pharmacokinetics Of Pf-02545920 In Psychiatrically Stable Subjects With Schizophrenia
To evaluate the safety and tolerability of multiple doses of PF 02545920 administered orally
to psychiatrically stable subjects with schizophrenia receiving background antipsychotic +/-
other adjunctive medication.
to psychiatrically stable subjects with schizophrenia receiving background antipsychotic +/-
other adjunctive medication.
Inclusion Criteria:
- Psychiatrically stable subjects with schizophrenia.
- Evidence of stable schizophrenia symptomatology greater than or equal to 3 months.
- Subjects must be on a stable medication treatment regimen greater than or equal to 2
months, including concomitant psychotropic medications.
Exclusion Criteria:
- History of seizures or of a condition with risk of seizures.
- Subjects who have had electroconvulsive therapy within the 6 months prior to
randomization.
- Pregnant or nursing females, and females of child bearing potential.
We found this trial at
1
site
Click here to add this to my saved trials
